WILMINGTON, Mass. & GHENT, Belgium--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Ziphius Vaccines, a biopharmaceutical company developing self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, today announced an agreement to manufacture starting materials critical to clinical-stage research.